tradingkey.logo
tradingkey.logo
Search

Anavex Life Sciences Corp

AVXL
Add to Watchlist
2.760USD
+0.180+6.98%
Close 07/02, 13:00ETQuotes delayed by 15 min
239.21MMarket Cap
LossP/E TTM

TradingKey Stock Score of Anavex Life Sciences Corp

Currency: USD Updated: 2026-07-02

Key Insights

Anavex Life Sciences Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 170 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Anavex Life Sciences Corp's Score

Industry at a Glance

Industry Ranking
170 / 387
Overall Ranking
314 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Anavex Life Sciences Corp Highlights

StrengthsRisks
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Overvalued
The company’s latest PE is -5.94, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 37.30M shares, increasing 2.73% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 47.50K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.11.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
20.000
Target Price
+675.19%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Anavex Life Sciences Corp?

The TradingKey Stock Score provides a comprehensive assessment of Anavex Life Sciences Corp based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Anavex Life Sciences Corp’s performance and outlook.

How do we generate the financial health score of Anavex Life Sciences Corp?

To generate the financial health score of Anavex Life Sciences Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Anavex Life Sciences Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Anavex Life Sciences Corp.

How do we generate the company valuation score of Anavex Life Sciences Corp?

To generate the company valuation score of Anavex Life Sciences Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Anavex Life Sciences Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Anavex Life Sciences Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Anavex Life Sciences Corp.

How do we generate the earnings forecast score of Anavex Life Sciences Corp?

To calculate the earnings forecast score of Anavex Life Sciences Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Anavex Life Sciences Corp’s future.

How do we generate the price momentum score of Anavex Life Sciences Corp?

When generating the price momentum score for Anavex Life Sciences Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Anavex Life Sciences Corp’s prices. A higher score indicates a more stable short-term price trend for Anavex Life Sciences Corp.

How do we generate the institutional confidence score of Anavex Life Sciences Corp?

To generate the institutional confidence score of Anavex Life Sciences Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Anavex Life Sciences Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Anavex Life Sciences Corp.

How do we generate the risk management score of Anavex Life Sciences Corp?

To assess the risk management score of Anavex Life Sciences Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Anavex Life Sciences Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Anavex Life Sciences Corp.